ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SNSS Sunesis Pharmaceuticals Inc

5.32
0.00 (0.00%)
16 Aug 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunesis Pharmaceuticals Inc NASDAQ:SNSS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.32 4.72 4.75 0 01:00:00

Sunesis Pharmaceuticals to Report Fourth Quarter and Full-Year 2007 Financial Results on March 11, 2008

05/03/2008 1:00pm

PR Newswire (US)


Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart


From Aug 2019 to Aug 2024

Click Here for more Sunesis Pharmaceuticals Charts.
SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on Tuesday, March 11, 2008 at 10:30 a.m. ET/7:30 a.m. PT to discuss financial results for the fourth quarter and fiscal year ended December 31, 2007. Individual and institutional investors can access the call via (877) 604- 9668 (U.S. and Canada) or (719) 325-4904 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com/. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. About Sunesis Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com/. DATASOURCE: Sunesis Pharmaceuticals, Inc. CONTACT: Investors, Eric Bjerkholt, SVP, Corp. Development & Finance of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or Media, Karen L. Bergman or Michelle Corral of BCC Partners, +1-650-575-1509 or +1-415-794-8662 Web site: http://www.sunesis.com/

Copyright

1 Year Sunesis Pharmaceuticals Chart

1 Year Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock